Literature DB >> 11948260

Clinical applications of (18)F-FDG in oncology.

Hani A Nabi1, José M Zubeldia.   

Abstract

PET has emerged as a powerful diagnostic tool for the evaluation of cancer patients. Currently, most of these studies are performed with the glucose analog (18)F-FDG, which has been shown to accumulate avidly in most tumors. (18)F-FDG PET is now routinely used in the diagnosis, staging, and posttherapy evaluation of oncologic patients. After reading this paper, the reader should understand the physiologic basis of using (18)F-FDG in patients with different tumors, describe the role of this radiopharmaceutical in the management of oncologic patients, and identify those malignancies for which (18)F-FDG has proved to be effective in diagnosis and follow-up.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11948260

Source DB:  PubMed          Journal:  J Nucl Med Technol        ISSN： 0091-4916


  21 in total

1.  Feasibility of perfusion CT technique integrated into conventional 18FDG/PET-CT studies in lung cancer patients: clinical staging and functional information in a single study.

Authors:  Davide Ippolito; Cristina Capraro; Luca Guerra; Elena De Ponti; Cristina Messa; Sandro Sironi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-10       Impact factor: 9.236

Review 2.  Image-guided nanosystems for targeted delivery in cancer therapy.

Authors:  A K Iyer; J He; M M Amiji
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide, resulting in enhanced melanoma uptake.

Authors:  Haixun Guo; Jianquan Yang; Fabio Gallazzi; Yubin Miao
Journal:  J Nucl Med       Date:  2010-02-11       Impact factor: 10.057

4.  Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice.

Authors:  Zhen Cheng; Jelena Levi; Zhengming Xiong; Olivier Gheysens; Shay Keren; Xiaoyuan Chen; Sanjiv Sam Gambhir
Journal:  Bioconjug Chem       Date:  2006 May-Jun       Impact factor: 4.774

5.  Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Authors:  Kaoru Kaseda; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

6.  Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide.

Authors:  Haixun Guo; Nalini Shenoy; Benjamin M Gershman; Jianquan Yang; Larry A Sklar; Yubin Miao
Journal:  Nucl Med Biol       Date:  2009-04       Impact factor: 2.408

7.  111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging.

Authors:  Yubin Miao; Fabio Gallazzi; Haixun Guo; Thomas P Quinn
Journal:  Bioconjug Chem       Date:  2008-01-16       Impact factor: 4.774

8.  Diffuse thyroid uptake incidentally found on 18F-fluorodeoxyglucose positron emission tomography in subjects without cancer history.

Authors:  Ji Young Lee; Joon Young Choi; Yoon-Ho Choi; Seung Hyup Hyun; Seung Hwan Moon; Su Jin Jang; Yearn Seong Choe; Kyung-Han Lee; Byung-Tae Kim
Journal:  Korean J Radiol       Date:  2013-05-02       Impact factor: 3.500

9.  Gallium-67-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide for primary and metastatic melanoma imaging.

Authors:  Haixun Guo; Jianquan Yang; Nalini Shenoy; Yubin Miao
Journal:  Bioconjug Chem       Date:  2009-12       Impact factor: 4.774

Review 10.  The role of positron emission tomography in germ cell cancer.

Authors:  Maria De Santis; Jörg Pont
Journal:  World J Urol       Date:  2004-03-16       Impact factor: 4.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.